Top Ten most popular articles on Pharmafile.com this week
pharmafile | September 7, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | EMA, MHRA, Trump, brexit, research, scandal, top 10
Brexit took the top two spots this week after it was revealed that the EMA has awarded Britain’s MHRA just two contracts this year, while GSK complained that Brexit will cost them $100 million. Meanwhile scandals have soured the first week of September as Sanofi settled charges of corruption with a $25 million dollar payment to the US while Dutch doctors campaigned against the price hiking Italian firm Leadiant Biosciences.
However in what is great news for young people suffering from leukaemia, Novartis’ CAR T therapy Kymriah, a one-time cancer treatment that uses a patient’s own immune cells in combatting cancer was accepted by NICE and thus will become available on the NHS.
To find out more, check out this week’s Top 10 most popular articles on Pharmafile.com now!
10. AI used to forecast cancer progression
A team of scientists at the Institute of Cancer Research in London and the University of Edinburgh have developed an artificial intelligence that is able to predict the ways in which cancers will progress and evolve. The technique may help doctors design personalised treatments.
9. Sanofi to pay $25m over Kazakhstan and Middle East corruption allegations
French pharma giant Sanofi will pay more than $25 million to settle corruption charges related to their subsidiaries in Kazakhstan and the Middle East.
8. Novartis sells key Sandoz US portfolios to Aurobindo for $1bn
Novartis has revealed it is to sell the dermatology and generic US oral solids portfolios of its generics arm Sandoz to Indian firm Aurobindo Pharma for $1 billion, in a move the company says will enable it to better achieve “sustainable and profitable growth in the US over the long-term”.
7. FDA turns to real-world evidence to improve regulatory process
The FDA is to incorporate real-world data elements to a greater degree into its regulatory decision-making framework in a bid to “answer questions that are relevant to broader patient populations or treatment settings where information may not be captured through traditional clinical trials.”
6. Novartis’ CAR T therapy Kymriah to become available on the NHS
Novartis’ Kymriah is set to become the first CAR T therapy to become available on the NHS after it was revealed that the cancer treatment will be offered to children and young adults up to the age of 25 years old with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse.
5. Dutch doctors resist pharma firm’s 500-fold price hike
A group of Dutch doctors and health advocates are taking action against the Italian pharmaceutical firm Leadiant Biosciences who have increased the price of a lifesaving drug by 500 times its original price.
4. Trump administration resists WHO efforts to tackle antimicrobial resistance
The Trump administration is in the process of drafting an alternative to the World Health Organization’s guidelines on the use of antimicrobial drugs in food producing animals. In resisting the WHO guidelines, which are intended to combat antimicrobial resistance, the move seems to benefit agribusiness.
3. GSK to axe 650 positions across US workforce
GlaxoSmithKline has announced its intention to cut 650 employees from its current US workforce, with the cutbacks coming as part of a global restructuring effort announced in July earlier this year.
2. Pfizer says Brexit will cost the company $100 million
The US multinational Pfizer has said that Brexit will cost the company $100 million in spend associated with the transference of product and testing licenses to other countries, alterations to clinical trial management procedures and other preventative measures.
1. MHRA loses EMA contracts in wake of Brexit
The EMA has awarded Britain’s regulatory body the MHRA just two contracts this year, as the European agency suggested that the uncertainty surrounding Brexit has made Britain off limits for new regulatory contracts.
Related Content
J&J gains positive CHMP opinion for Rybrevant for treatment of lung cancer
Janssen, a Johnson & Johnson (J&J) company, has announced that the Committee for Medicinal Products …
Ascendis Pharma’s Yorvipath approved by MHRA for hypoparathyroidism treatment
Ascendis Pharma has announced that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has …
MHRA approves Takeda’s Hyqvia for chronic inflammatory demyelinating polyneuropathy treatment
Takeda has announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing …
